^
Association details:
Biomarker:SDHB mutation + SDHD mutation
Cancer:Neuroendocrine Tumor
Regimen: (cisplatin + dacarbazine + vinblastine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Outcomes of systemic treatment in patients with metastatic pheochromocytoma and paraganglioma: A single center retrospective analysis.

Published date:
02/13/2023
Excerpt:
Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors arising from chromaffin cells...33 patients were diagnosed with metastatic PPGLs and received systemic treatment....In CVD treatment, patients with SDHB/SDHD mutation (either germline or somatic) were significantly associated with superior OS & PFS compared with the non-SDHB/SDHD mutation group, with a median OS of 94.0 months vs. 5.7 months (P = 0.01) and a median PFS of 20.1 months vs. 1.6 months (P = 0.03), respectively. In the SDHB/SDHD mutation group, the ORR was 50% (3/6, all PR), and the DCR was 100% (n=6), but in a non-SDHB/SDHD mutation group, the ORR was 11% (1/9, PR) and the DCR was 44% (n=4).
DOI:
10.1200/JCO.2023.41.6_suppl.2